Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2018;35(2):115-122.
doi: 10.36141/svdld.v35i2.6257. Epub 2018 Apr 28.

NOD2/CARD15 gene polymorphisms and sarcoidosis susceptibility: review and meta-analysis

Xuping Chen  1 , Zhenxing Zhou  1 , Yi Zhang  1 , Xiaoliang Cheng  1 , Xiaowen Guo  1 , Xiaodong Yang  1
Affiliations
Review

NOD2/CARD15 gene polymorphisms and sarcoidosis susceptibility: review and meta-analysis

Xuping Chen et al. Sarcoidosis Vasc Diffuse Lung Dis. 2018.

Abstract

Background: The association between NOD2/CARD15 (nucleotide binding oligomerisation domain containing 2) gene polymorphisms and susceptibility to sarcoidosis have been extensively investigated in recent years. However, the results from previous studies remain controversial. To assess the association of NOD2/CARD15 polymorphisms and sarcoidosis susceptibility, we performed a meta-analysis. Methods: PubMed, Embase, CNKI and Wanfang databases were examined for all relevant studies up until 8th October 2016. In all, 968 cases and 1549 controls in eight case-control studies were included which mainly consisted of Caucasian participants. The relevant data were extracted and the odds ratio (OR) with 95% confidence intervals (95% CI) calculated to assess the strength of any associations. Statistical analyses were calculated using STATA12.0 software and Revman5.3 software. The associations between NOD2/CARD15 SNP rs2066844, rs2066845, rs2066847, rs1861759 polymorphisms and the risk of sarcoidosis were evaluated in allelic, dominant, recessive and additive models. Results: The pooled data showed that the NOD2/CARD15 rs2066845 polymorphism was associated with sarcoidosis susceptibility in allelic model (C vs. G, OR=1.86, 95% CI: 1.14-3.04, P=0.01), dominant model (GC + CC vs. GG, OR=1.84, 95% CI: 1.11-3.05, P=0.02) and additive model (GC vs. GG, OR=1.79, 95% CI: 1.08-2.97, P=0.02). However, the results suggested that the rs2066844, rs2066847 and rs1861759 polymorphisms might not be associated with a risk of sarcoidosis. Conclusions: This meta-analysis indicated that the 'C' allele of SNP rs2066845 may be a risk factor for sarcoidosis, especially in Caucasians, whilst rs2066844, rs2066847 and rs1861759 may not be associated with a risk of developing sarcoidosis. (Sarcoidosis Vasc Diffuse Lung Dis 2018; 35: 115-122).

Keywords: CARD15. genetic susceptibility; meta-analysis; polymorphism; sarcoidosis.

PubMed Disclaimer

Figures

Fig. 1.
Fig. 1.
The flow diagram of included and excluded studies
Fig. 2.
Fig. 2.
Forest plots of OR with 95% CI for the association between rs2066845 and risk of sarcoidosis with results both in overall and removing ‘H.sato 2010’ analysis in allelic model(a), dominant model (b), and additive model (c) independently
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Statement on sarcoidosis. Joint Statement of the American Thoracic Society (ATS), the European Respiratory Society (ERS) and the World Association of Sarcoidosis and Other Granulomatous Disorders (WASOG) adopted by the ATS Board of Directors and by the ERS Executive Committee, February 1999. Am J Respir Crit Care Med. 1999;160:736–55. - PubMed
    1. Hugot JP, Chamaillard M, Zouali H, et al. Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn’s disease. Nature. 2001;411:599–603. - PubMed
    1. Mann JK, Shen J, Park S. Enhancement of Muramyl Dipeptide-Dependent NOD2 activity by a self-derived peptide. J Cell Biochem. 2016;9999:1–12. - PubMed
    1. Schurmann M, Valentonyte R, Hampe J, et al. CARD15 gene mutations in sarcoidosis. Eur Respir J. 2003;22:748–54. - PubMed
    1. Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement. Int J Surg. 2010;8:336–41. - PubMed

LinkOut - more resources